Global CAR T-Cell Immunotherapy Market by Type (Monotherapy and Combination Therapy), By Application (Hematologic Malignancies and Solid Malignancies) Industry Analysis, Size, Share, Growth, Trends, and Forecasts 2019-2025
Esticast Research and Consulting offers the latest published report on Global CAR T-Cell Immunotherapy Market Analysis and Forecast from 2019 to 2026 delivering key insights and providing a competitive advantage to clients through a detailed report. Additionally, the report focuses on CAR T-Cell Immunotherapy industry key players, to define and analyze the sales volume, value, market share, market competitive landscape, and recent developments.
Global CAR T-Cell Immunotherapy market is estimated to reach $ 3.21 Billion by 2025.
About Global CAR T-Cell Immunotherapy Market
Firstly, the report offers a basic overview of the industry including, definitions, classifications, applications, and industry chain scenario. The CAR T-Cell Immunotherapy industry analysis is provided for the global market including development history, segment analysis, major regional developments, and a thorough competitor's evaluation.
Secondly, growth policies and plans are reviewed as well as manufacturing processes and cost structures. This report also discusses supply and consumption figures, import/export data, cost, price, revenue and gross margins by prime regions such as the U.S. Europe, China, and Japan along with other key regions. Moreover, Global CAR T-Cell Immunotherapy Market proposes market trend analysis, drivers, and challenges by consumer behavior, and various marketing channels.
Competitive Glimpse
Top listed manufacturers for Global Global CAR T-Cell Immunotherapy Market are:
AbbVie Inc.
Celgene Corporation
Kite Pharma
Oxford BioMedica
Novartis International AG
Gilead Sciences, Inc.
Pfizer, Inc.
Cellectis
Bellicum Pharmaceuticals, Inc.
Mustang Bio
CARsgen Therapeutics Ltd
Xyphos
Minerva Biotechnologies
Adaptimmune
Ziopharm Oncology, Inc.
With the slowdown in world economic growth, the CAR T-Cell Immunotherapy industry has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years.
How has the competitive landscape of this industry been categorized?
The competitive scope of Global CAR T-Cell Immunotherapy Market spans firms listed above, as per the report.
The report includes substantial information pertaining to the produced goods, company profile, revenue graph, as well as other production patterns.
The research study also presents details with respect to the market share that every company accounts for, as well as gross margins and price prototypes of the products.
Market Segmentation:
Esticast Research offers a crystal clear view of the various sections such as segmental analysis, regional analyst, product portfolios, followed by detailed information about market leaders and their strategies about mergers and acquisitions.
By Type
Monotherapy
Combination Therapy
By Application
Hematologic Malignancies
Solid Malignancies
Geographically, this report studies the top producers and consumers, focuses on product capacity, production, value, consumption, market share and growth opportunity in these key regions, covering
North America
Europe
Asia-Pacific
South America
The Middle East and Africa
Reasons to access this report:
Esticast Research and Consulting report is designed in a method that assists clients to gain a complete knowledge of the complete market scenario and the important sectors.
This report consists of meticulous overview of market dynamics, and thorough research.
Explore further market prospects and identify high potential categories based on comprehensive volume and value analysis
Detail information on competitive landscape, current market trends and evolving technologies that can be useful for the companies which are competing in this market
Gaining knowledge about competitive landscape based on thorough brand share analysis to plan an active market positioning
Table of Content
1. Market Introduction
1.1. Executive Summary
1.2. Market Definition
1.3. Market Scope
2. Research Methodology
2.1. Primary Research
2.2. Research Methodology
2.3. Assumptions & Exclusions
2.4. Secondary data sources
3. CAR T-Cell Immunotherapy Market Overview
3.1. Report Segmentation & Scope
3.2. Key Market Trend
3.3. Drivers
3.3.1. Increasing healthcare insurance and expenditure with better healthcare infrastructure
3.3.2. Approvals from US food and drug administration for cancer therapies
3.3.3. Growing prevalence and incidence of cancer across the globe
3.4. Restraints
3.4.1. Less experienced healthcare professionals
3.4.2. Lack of awareness about such therapies among the population
3.5. Opportunity
3.5.1. Increasing technological advancement in various treatment therapies
3.5.2. Increasing CAR-T cell research investments by leading players
3.6. Porter's Five Forces Analysis
3.6.1. Porter's Five Forces Analysis
3.7. Market Share Analysis
4. Type Overview
4.1. Introduction
4.1.1. Market Size & Forecast
4.2. Monotherapy
4.2.1. Market Size & Forecast
4.3. Combination Therapy
4.3.1. Market Size & Forecast
5. Application Overview
5.1. Introduction
5.1.1. Market Size & Forecast
5.2. Hematologic Malignancies
5.2.1. Market Size & Forecast
5.3. Solid Malignancies
5.3.1. Market Size & Forecast
6. CAR T-Cell Immunotherapy Market Regional Overview
6.1. Introduction
6.1.1. Market Size & Forecast
6.2. North America CAR T-Cell Immunotherapy Market
6.2.1. North America Market Size & Forecast, By Country
6.2.2. North America Market Size & Forecast, By Type
6.2.3. North America Market Size & Forecast, By Application
6.2.4. The U.S.
6.2.4.1. Market Size and Forecast
6.2.5. Canada
6.2.5.1. Market Size and Forecast
6.2.6. Mexico
6.2.6.1. Market Size and Forecast
6.3. Europe CAR T-Cell Immunotherapy Market
6.3.1. Europe Market Size & Forecast, By Country
6.3.2. Europe Market Size & Forecast, By Type
6.3.3. Europe Market Size & Forecast, By Application
6.3.4. Germany
6.3.4.1. Market Size and Forecast
6.3.5. France
6.3.5.1. Market Size and Forecast
6.3.6. UK
6.3.6.1. Market Size and Forecast
6.3.7. Italy
6.3.7.1. Market Size and Forecast
6.3.8. Spain
6.3.8.1. Market Size and Forecast
6.3.9. Rest of Europe
6.3.9.1. Market Size and Forecast
6.4. Asia-Pacific CAR T-Cell Immunotherapy Market
6.4.1. Asia-Pacific Market Size & Forecast, By Country
6.4.2. Asia-Pacific Market Size & Forecast, By Type
6.4.3. Asia-Pacific Market Size & Forecast, By Application
6.4.4. Japan
6.4.4.1. Market Size and Forecast
6.4.5. China
6.4.5.1. Market Size and Forecast
6.4.6. Australia
6.4.6.1. Market Size and Forecast
6.4.7. India
6.4.7.1. Market Size and Forecast
6.4.8. South Korea
6.4.8.1. Market Size and Forecast
6.4.9. Rest of Asia-Pacific
6.4.9.1. Market Size and Forecast
6.5. South America CAR T-Cell Immunotherapy Market
6.5.1. South America Market Size & Forecast, By Country
6.5.2. South America Market Size & Forecast, By Type
6.5.3. South America Market Size & Forecast, By Application
6.5.4. Brazil
6.5.4.1. Market Size and Forecast
6.5.5. Argentina
6.5.5.1. Market Size and Forecast
6.5.6. Rest of South America
6.5.6.1. Market Size and Forecast
6.6. The Middle East & Africa CAR T-Cell Immunotherapy Market
6.6.1. The Middle East & Africa Market Size & Forecast, By Country
6.6.2. The Middle East & Africa Market Size & Forecast, By Type
6.6.3. The Middle East & Africa Market Size & Forecast, By Application
6.6.4. GCC Countries
6.6.4.1. Market Size and Forecast
6.6.5. Egypt
6.6.5.1. Market Size and Forecast
6.6.6. South Africa
6.6.6.1. Market Size and Forecast
6.6.7. Rest of Middle East & Africa
6.6.7.1. Market Size and Forecast
7. Company Profile
7.1. AbbVie Inc.
7.1.1. Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.1.2. AbbVie Inc. Product Category, Application, and Specification
7.1.3. AbbVie Inc. Financial Performance (2016-2018)
7.1.4. Main Business/Business Overview
7.2. Celgene Corporation
7.3. Kite Pharma
7.4. Oxford BioMedica
7.5. Novartis International AG
7.6. Gilead Sciences, Inc.
7.7. Pfizer, Inc.
7.8. Cellectis
7.9. Bellicum Pharmaceuticals, Inc.
7.10. Mustang Bio
7.11. CARsgen Therapeutics Ltd
7.12. Xyphos
7.13. Minerva Biotechnologies
7.14. Adaptimmune
7.15. Ziopharm Oncology, Inc.
Tables and Figures
Reason to Buy
- Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
- Highlights key business priorities in order to assist companies to realign their business strategies
- The segment that is expected to dominate the Pharma & Healthcare Market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets